Amerikanische Gesellschaft für Hirudotherapie

Mechanical leech therapy to relieve venous congestion

Experimental study published in J Reconstr Microsurg (1995)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyKlinische StudienSmoot EC et al. · Journal of reconstructive microsurgery, 1995

Abstract

When faced with venous insufficiency following replantation or free-tissue transfer, the surgeons' first choice is surgical repair. When repair is not possible, medicinal leeches may be applied to relieve congestion. However, leeches increase the possibility of infection through their gut contents, and there are times when the available leech supply is short and the need for rapid exsanguination is great. A mechanical device has been developed and tested which could be used as a substitute for the medicinal leech. Using a venous-congested rat epigastric flap, this device was demonstrated to be superior to a medicinal leech in restoring capillary perfusion to the flap during the first hour of exsanguination. The device may offer an alternative to the medicinal leech for the clinical treatment of small areas of tissue with venous congestion.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAnimalsLeechesPostoperative ComplicationsRatsRats, WistarSuctionSurgical FlapsVenous Insufficiency

Zusammenfassung

Mechanical device tested as substitute for medicinal leech in rat venous congested flap model demonstrated superior capillary perfusion restoration in first hour of exsanguination versus leech.

Warum dies für die Hirudotherapie relevant ist

This comparative study evaluated a prototype mechanical exsanguination device against medicinal leeches in a rat epigastric venous-congestion flap model, finding the device superior to a leech in restoring capillary perfusion during the first hour of treatment, and positioning it as a potential alternative to live leeches. For ASH, this is relevant because it directly benchmarks hirudotherapy against a mechanical substitute, addressing known drawbacks of live leeches (infection risk, supply constraints). Honest caveat: this is an animal-model (rat) study with short-term (first-hour) perfusion as the only reported outcome, no human data, and no assessment of infection or flap survival; the mechanical device is proposed as an alternative, not validated clinically.

Zitation

Mechanical leech therapy to relieve venous congestion.

Smoot EC et al. · Journal of reconstructive microsurgery, 1995

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.